Stryker (NYSE:SYK) Price Target Lowered to $418.00 at Needham & Company LLC

Stryker (NYSE:SYK) had its price objective lowered by equities research analysts at Needham & Company LLC from $454.00 to $418.00 in a report issued on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the medical technology company’s stock. Needham & Company LLC’s target price indicates a potential upside of 32.85% from the stock’s previous close.

Several other brokerages have also recently issued reports on SYK. Barclays reiterated an “overweight” rating and issued a $469.00 price objective on shares of Stryker in a research note on Monday, February 2nd. BTIG Research reiterated a “buy” rating and issued a $397.00 price objective on shares of Stryker in a research note on Tuesday, April 14th. TD Cowen cut Stryker from a “buy” rating to a “hold” rating and set a $387.00 price objective on the stock. in a research note on Monday, January 26th. Jefferies Financial Group reiterated a “buy” rating and issued a $465.00 price objective on shares of Stryker in a research note on Wednesday, March 4th. Finally, Evercore set a $390.00 price objective on Stryker in a research note on Monday, January 5th. Fifteen investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $418.26.

Stryker Stock Down 0.2%

NYSE:SYK opened at $314.64 on Friday. The company has a quick ratio of 1.21, a current ratio of 1.89 and a debt-to-equity ratio of 0.66. The stock’s fifty day moving average is $345.67 and its two-hundred day moving average is $356.95. Stryker has a 52 week low of $311.31 and a 52 week high of $404.87. The stock has a market capitalization of $120.50 billion, a price-to-earnings ratio of 37.46, a price-to-earnings-growth ratio of 1.84 and a beta of 0.92.

Stryker (NYSE:SYK) last released its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). Stryker had a return on equity of 24.41% and a net margin of 12.92%.The firm had revenue of $6.02 billion for the quarter, compared to analyst estimates of $6.34 billion. During the same quarter last year, the company earned $2.84 earnings per share. The firm’s revenue for the quarter was up 2.6% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Research analysts anticipate that Stryker will post 14.91 EPS for the current year.

Insider Buying and Selling

In related news, Director Ronda E. Stryker sold 250,000 shares of the stock in a transaction on Wednesday, February 4th. The stock was sold at an average price of $362.92, for a total value of $90,730,000.00. Following the transaction, the director owned 2,457,331 shares of the company’s stock, valued at $891,814,566.52. This represents a 9.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 4.60% of the stock is owned by company insiders.

Hedge Funds Weigh In On Stryker

Large investors have recently bought and sold shares of the business. Sankala Group LLC purchased a new position in Stryker in the fourth quarter valued at $26,000. Godfrey Financial Associates Inc. purchased a new position in shares of Stryker during the fourth quarter worth about $26,000. United Financial Planning Group LLC purchased a new position in shares of Stryker during the third quarter worth about $27,000. Atlas Capital Advisors Inc. purchased a new position in shares of Stryker during the fourth quarter worth about $27,000. Finally, DJE Kapital AG purchased a new position in shares of Stryker during the fourth quarter worth about $28,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

More Stryker News

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Management kept FY‑2026 guidance intact — organic sales growth of 8%–9.5% and adjusted EPS of $14.90–$15.10, signaling confidence in medium‑term demand and execution. Stryker maintains 2026 outlook
• Positive Sentiment: Cash flow and GAAP net income showed strength (operating cash from ops surged year‑over‑year; reported profit rose to $745M), providing balance‑sheet flexibility. Q1 results: cash flow & net income up
• Positive Sentiment: Company says it has largely recovered operationally from the cyber incident, which management says disrupted the quarter but is being contained. That supports the decision to keep guidance. Stryker reports first quarter 2026 operating results
• Neutral Sentiment: Full Q1 press conference transcript and management commentary are available for details on recovery timing, regional trends and product‑line performance — useful for assessing forward visibility. Q1 2026 press conference transcript
• Negative Sentiment: Q1 adjusted EPS of $2.60 missed the consensus (~$2.98) and revenue of $6.02B fell short of estimates (~$6.34B), a headline miss that pressured the stock. Q1 earnings snapshot / consensus miss
• Negative Sentiment: Management cited softer demand for implants and complex‑procedure devices (orthopaedics, spine) and adjusted operating margin contraction (~180 bps), suggesting near‑term revenue headwinds even as recovery from the cyber event continues. Reuters: misses estimates on muted demand

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.